Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
John M. Sorensen
Observed names:
J M Sorensen,
J. M. Sorensen,
J. Mel Sorensen,
J.M. Sorensen
Institution:
Galera Therapeutics, Inc. (United States)
Observed institutions:
Brooke Army Medical Center,
National Institutes of Health,
National Cancer Institute,
Galera Therapeutics, Inc. (United States),
Massachusetts Institute of Technology
OpenAlex ID:
A5028595129
Fundamental Frequency in Sentence Production
1981
·
William E. Cooper
, John M. Sorensen
·
Springer eBooks
·
365
Inhibition of fluorouracil-induced stomatitis by oral cryotherapy.
1991
·
D J Mahood
, A M Dose
, et al.
·
Journal of Clinical Oncology
·
272
Neurotoxicity of purine analogs: a review.
1994
·
B D Cheson
, D A Vena
, et al.
·
Journal of Clinical Oncology
·
202
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients.
1998
·
B D Cheson
, J M Sorensen
, et al.
·
Journal of Clinical Oncology
·
160
Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.
1997
·
B C Widemann
, F M Balis
, et al.
·
Journal of Clinical Oncology
·
127
A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.
1991
·
J L Grem
, N McAtee
, et al.
·
Journal of Clinical Oncology
·
117
Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report.
1997
·
J M Sorensen
, D A Vena
, et al.
·
Journal of Clinical Oncology
·
110
Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid Malignancies
2000
·
Eric K. Rowinsky
, Rachel Humphrey
, et al.
·
Journal of Clinical Oncology
·
86
Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study
2015
·
Herbert I. Hurwitz
, David C. Smith
, et al.
·
Cancer Chemotherapy and Pharmacology
·
83
PDF
Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia.
1998
·
B D Cheson
, J N Frame
, et al.
·
Journal of Clinical Oncology
·
81
Speech timing of grammatical categories
1978
·
John M. Sorensen
, William E. Cooper
, et al.
·
Cognition
·
64
Oral Debio1143 (AT406), an Antagonist of Inhibitor of Apoptosis Proteins, Combined With Daunorubicin and Cytarabine in Patients With Poor-Risk Acute Myeloid Leukemia—Results of a Phase I Dose-Escalation Study
2015
·
John F. DiPersio
, Harry P. Erba
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
47
Clinical use of thymidine as a rescue agent from methotrexate toxicity
1991
·
Jean L. Grem
, Susan A. King
, et al.
·
Investigational New Drugs
·
24
A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.
1999
·
J L Grem
, J M Sorensen
, et al.
·
PubMed
·
20
New drugs in non-Hodgkin's lymphoma
1997
·
S.G. Arbuck
, J.M. Sorensen
, et al.
·
Annals of Oncology
·
14
Current Status of U.S. Clinical Trials in Chronic Lymphocytic Leukemia
1991
·
Bruce D. Cheson
, Don A. Vena
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
10
Correlations of duration for nonadjacent segments in speech: Aspects of grammatical coding
1977
·
William E. Cooper
, John M. Sorensen
, et al.
·
The Journal of the Acoustical Society of America
·
6
A pilot study of gamma-1b-interferon in combination with fluorouracil, leucovorin, and alpha-2a-interferon.
1997
·
J L Grem
, N McAtee
, et al.
·
PubMed
·
5
Untitled
1997
·
S. G. Arbuck
, J. M. Sorensen
, et al.
·
Annals of Oncology
·
5
First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results.
2014
·
Herbert Hurwitz
, Henry Clement Pitot
, et al.
·
Journal of Clinical Oncology
·
3
76 Preliminary Report of a First-in-human, Open-label, Multicenter, Phase I Study of AT-406 (Debio 1143), an Oral Small Molecule Multi-IAP Inhibitor, in Solid Tumors and Lymphomas
2012
·
H. Hurwitz
, H. Pitot
, et al.
·
European Journal of Cancer
·
3
Introduction
1981
·
William E. Cooper
, John M. Sorensen
·
Springer eBooks
·
3
Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML).
2014
·
John F. DiPersio
, Harry Paul Erba
, et al.
·
Journal of Clinical Oncology
·
2
A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
1997
·
G Colón-Otero
, R Marschke
, et al.
·
PubMed
·
1
CLO19-037: Reducing the Duration, Incidence and Severity of Mucosal Injury Due to Cancer Radiation therapy (RT); Positive Randomized Phase 2b Trial Results With GC4419 (Avasopasem Manganese), a Small Molecule Superoxide (SO) Dismutase (SOD) Mimetic
2019
·
Jon T. Holmlund
, Carryn M. Anderson
, et al.
·
Journal of the National Comprehensive Cancer Network
Show more works
View as search
Works count:
33
Citation count:
1,810
H-index:
14
I10-index:
16
Year
Topic
Type